目的探讨三联疗法治疗H p阳性FD患者消化不良症状的疗效。方法将145例H p阳性的功能性消化不良患者随机分为治疗组和对照组,治疗组73例在遵循综合和个体化治疗原则上,予雷贝拉唑10 m g+克拉霉素0.5 g+阿莫西林1 g,均2次/d,疗程均为1周;...目的探讨三联疗法治疗H p阳性FD患者消化不良症状的疗效。方法将145例H p阳性的功能性消化不良患者随机分为治疗组和对照组,治疗组73例在遵循综合和个体化治疗原则上,予雷贝拉唑10 m g+克拉霉素0.5 g+阿莫西林1 g,均2次/d,疗程均为1周;对照组72例遵循综合和个体化治疗原则基础上,给予雷贝拉唑10 m g,1次/d+莫沙必利10 m g,3次/d,疗程均为1周,随访2组1个月及1年后症状积分的改善情况。结果2组FD患者1个月及1年后症状积分疗效比较,治疗组中总有效率为58.9%和24.6%;对照组中总有效率为27.8和6.9%,2组比较有显著性差异,P均<0.01。结论三联疗法治疗H p阳性的功能性消化不良患者,可消除或明显改善消化不良症状。展开更多
BACKGROUND:The treatment of patients with functional dyspepsia remains unsatisfactory.We assessed the efficacy of itopride,a dopamine D2 antagonist with acetylcholinesterase effects,in patients with functional dyspeps...BACKGROUND:The treatment of patients with functional dyspepsia remains unsatisfactory.We assessed the efficacy of itopride,a dopamine D2 antagonist with acetylcholinesterase effects,in patients with functional dyspepsia.METHODS:Patients with functional dyspepsia were randomly assigned to receive either itopride(50,100,or 200 mg three times daily)or placebo.After eight weeks of treatment,three primary efficacy end points were analyzed:the change from baseline in the severity of symptoms of functional dyspepsia(as assessed by the Leeds Dyspepsia Questionnaire),patients’global assessment of efficacy(the proportion of patients without symptoms or with marked improvement),and the severity of pain or fullness as rated on a five-grade scale.RESULTS:We randomly assigned 554 patients;523 had outcome data and could be included in the analyses.After eight weeks,41 percent of the patients receiving placebo were symptom-free or had marked improvement,as compared with 57 percent,59 percent,and 64 percent receiving itopride at a dose of 50,100,or 200 mg three times daily,respectively(P < 0.05 for all comparisons between placebo and itopride).Although the symptom score improved significantly in all four groups,an overall analysis revealed that itopride was significantly superior to placebo,with the greatest symptom-score improvement in the 100 and 200 mg groups(-6.24 and-6.27,vs.-4.50 in the placebo group;P = 0.05).Analysis of the combined end point of pain and fullness showed that itopride yielded a greater rate of response than placebo(73 percent vs.63 percent,P = 0.04).CONCLUSIONS:Itopride significantly improves symptoms in patients with functional dyspepsia.展开更多
AIM: To investigate in patients with functional dyspepsia (FD) after an every-day meal whether (1) gastrointestinal (GI) and extra-GI symptoms had any relation with the degree of antral volume, (2) the onset of postpr...AIM: To investigate in patients with functional dyspepsia (FD) after an every-day meal whether (1) gastrointestinal (GI) and extra-GI symptoms had any relation with the degree of antral volume, (2) the onset of postprandial symptoms was associated with, and may predict, delayed gastric emptying. METHODS: In 94 symptomatic FD patients, antral volume variations and gastric emptying were assessed with ultrasonography after a 1050 kcal meal. Symptoms were evaluated with a standardized questionnaire. The association of GI and extra-GI symptoms with antral volumes and gastric emptying were estimated with logistic regression analysis. RESULTS: Forty percent of patients did not report any symptoms after a meal. Compared to the healthy controls, the antrum was more distended in patients throughout the entire observation period and 37 (39.4%) patients had delayed gastric emptying. Only postprandial drowsiness was associated with antral volume variations (AOR = 1.42; P < 0.001) and with delayed gastric emptying (AOR = 3.59; P < 0.03). CONCLUSION: In FD patients, GI symptoms are neither associated with antral distension nor with gastric emptying. Drowsiness is associated with antral distension and delayed gastric emptying. The onset of drowsiness is preceded by an increment of antral distension and the duration of the symptom appears to be related to the persistence of antral distension.展开更多
文摘目的探讨三联疗法治疗H p阳性FD患者消化不良症状的疗效。方法将145例H p阳性的功能性消化不良患者随机分为治疗组和对照组,治疗组73例在遵循综合和个体化治疗原则上,予雷贝拉唑10 m g+克拉霉素0.5 g+阿莫西林1 g,均2次/d,疗程均为1周;对照组72例遵循综合和个体化治疗原则基础上,给予雷贝拉唑10 m g,1次/d+莫沙必利10 m g,3次/d,疗程均为1周,随访2组1个月及1年后症状积分的改善情况。结果2组FD患者1个月及1年后症状积分疗效比较,治疗组中总有效率为58.9%和24.6%;对照组中总有效率为27.8和6.9%,2组比较有显著性差异,P均<0.01。结论三联疗法治疗H p阳性的功能性消化不良患者,可消除或明显改善消化不良症状。
文摘BACKGROUND:The treatment of patients with functional dyspepsia remains unsatisfactory.We assessed the efficacy of itopride,a dopamine D2 antagonist with acetylcholinesterase effects,in patients with functional dyspepsia.METHODS:Patients with functional dyspepsia were randomly assigned to receive either itopride(50,100,or 200 mg three times daily)or placebo.After eight weeks of treatment,three primary efficacy end points were analyzed:the change from baseline in the severity of symptoms of functional dyspepsia(as assessed by the Leeds Dyspepsia Questionnaire),patients’global assessment of efficacy(the proportion of patients without symptoms or with marked improvement),and the severity of pain or fullness as rated on a five-grade scale.RESULTS:We randomly assigned 554 patients;523 had outcome data and could be included in the analyses.After eight weeks,41 percent of the patients receiving placebo were symptom-free or had marked improvement,as compared with 57 percent,59 percent,and 64 percent receiving itopride at a dose of 50,100,or 200 mg three times daily,respectively(P < 0.05 for all comparisons between placebo and itopride).Although the symptom score improved significantly in all four groups,an overall analysis revealed that itopride was significantly superior to placebo,with the greatest symptom-score improvement in the 100 and 200 mg groups(-6.24 and-6.27,vs.-4.50 in the placebo group;P = 0.05).Analysis of the combined end point of pain and fullness showed that itopride yielded a greater rate of response than placebo(73 percent vs.63 percent,P = 0.04).CONCLUSIONS:Itopride significantly improves symptoms in patients with functional dyspepsia.
文摘AIM: To investigate in patients with functional dyspepsia (FD) after an every-day meal whether (1) gastrointestinal (GI) and extra-GI symptoms had any relation with the degree of antral volume, (2) the onset of postprandial symptoms was associated with, and may predict, delayed gastric emptying. METHODS: In 94 symptomatic FD patients, antral volume variations and gastric emptying were assessed with ultrasonography after a 1050 kcal meal. Symptoms were evaluated with a standardized questionnaire. The association of GI and extra-GI symptoms with antral volumes and gastric emptying were estimated with logistic regression analysis. RESULTS: Forty percent of patients did not report any symptoms after a meal. Compared to the healthy controls, the antrum was more distended in patients throughout the entire observation period and 37 (39.4%) patients had delayed gastric emptying. Only postprandial drowsiness was associated with antral volume variations (AOR = 1.42; P < 0.001) and with delayed gastric emptying (AOR = 3.59; P < 0.03). CONCLUSION: In FD patients, GI symptoms are neither associated with antral distension nor with gastric emptying. Drowsiness is associated with antral distension and delayed gastric emptying. The onset of drowsiness is preceded by an increment of antral distension and the duration of the symptom appears to be related to the persistence of antral distension.
